Vascular Biogenics (VBLT) Breakout Move; United Continental (UAL), Delta Air Lines (DAL) Seen as Potential Bidders for Avianca Holdings (AVH)


Shares of Vascular Biogenics Ltd. (Nasdaq:VBLT) soared more than 40% in after-hours trading Friday as the clinical stage biopharmaceutical company said that a combination of its anti-cancer gene-therapy agent VB-111 with Avastin(R) (bevacizumab) demonstrated – in a Phase 2 study – a significant survival benefit in recurrent glioblastoma (rGBM) patients versus Avastin alone

VBLT stock finished the regular session at $3.97, up $0.18 (or +4.75%) and 357,782 of its shares changed hands during the day, a large increase in activity versus its average volume (3m) of 56,106

Vascular Biogenics, which focuses on the discovery, development and commercialization of first-in-class treatments for cancer, has 22.48M Shares Outstanding, Market Capitalization (intraday) of $89.24M and VBLT stock 52-week range is from $2.76 to $12.25 per share



Avianca Holdings S.A. (NYSE:AVH) shares climbed to touch the $6.78 mark during Friday’s trading session, following a report by the Wall Street Journal indicating that giants United Continental Holdings, Inc. (NYSE:UAL) and Delta Air Lines, Inc. (NYSE:DAL) are among suitors considering bids for the company that integrates several Latin American airlines under the Avianca brand.

AVH stock finally closed at $6.51, up $1.33 (or +25.68%) with a total volume of 2,814,477 shares traded

Avianca Holdings, which provides air transportation services, has 124.62M Shares Outstanding, Market Capitalization (intraday) of $811.30M and AVH stock one-year range is between $3.40 and $11.08 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at